Kesselheim leads the Program on Regulation, Therapeutics, and Law, an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. His research focuses on the effects of intellectual property laws and regulatory policies on pharmaceutical development, the drug approval process, and the costs, availability, and use of prescription drugs both domestically and in resource-poor settings. Kesselheim’s work on this study was supported by the Greenwall Faculty Scholar in Bioethics.